Neurosurgeons at UC San Diego Health System are the first in Southern California to implant a deep brain stimulator (DBS) in a patient with Parkinson’s disease using real-time 3-D magnetic resonance image (MRI) guidance.
Thomas Savides, MD has been named as the first Chief Experience Officer at UC San Diego Health System. In the newly created role, Savides will be responsible for the strategy, leadership and implementation of the plan to improve the total health care experience of patients, families, providers and staff.
For the second time, The Leapfrog Group has named UC San Diego Health System to its annual list of Top Hospitals. Awarded to hospitals nationwide for demonstrating excellence in hospital safety and quality, the Leapfrog Top Hospital award is an elite distinction given to less than seven percent of all…
UC San Diego Health System and Imperial Valley Family Care Medical Group (IVFCMG) are pleased to announce a comprehensive affiliation that will enhance the depth and quality of multi-specialty health care services and clinical trials available to patients in the Imperial Valley and surrounding communities.
UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association (HAEA), a non-profit patient advocacy organization, has opened the nation’s first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema.
Bess Marcus, PhD, has been appointed senior associate dean for Public Health with the UC San Diego School of Medicine.
Thomas Moore, MD has been named dean of Clinical Affairs and CEO for Faculty Practice at UC San Diego Health Sciences.
Updating its unique Hospital Safety Score, which assigns A, B, C, D and F grades to hospitals nationwide based on their ability to prevent errors, injuries and infections, UC San Diego Health System has again been awarded separate A ratings for its hospitals in Hillcrest and La Jolla by The Leapfrog…
UC San Diego Sanford Stem Cell Clinical Center is pushing therapeutic stem cell-based science out of the laboratory and closer to real-world medical applications. The unprecedented trials involve potential therapies for spinal cord injuries, Type 1 diabetes and chronic lymphocytic leukemia.
Researchers at the University of California, San Diego School of Medicine have identified a new fusion protein found in approximately 15 percent of secondary glioblastomas or brain tumors. The finding offers new insights into the cause of this cancer and provides a therapeutic target for personalized…